Abstract
The neuropharmacological profile of Y-931, 8-fluoro-12- (4-methylpiperazin-1-yl)- 6H-[1]benzothieno [2,3-b][1,5]benzodiazepine maleate, was investigated in comparison with those of typical and claimed atypical antipsychotic drugs. Similar to clozapine and olanzapine, Y-931 interacted with multiple neurotransmitter receptors such as dopaminergic, serotonergic, alpha-adrenergic, muscarinic and histaminergic receptors. Y-931, as well as the other antipsychotics, was active in a dose-dependent manner in established tests which are indicative of potential antipsychotic activity such as inhibition of apomorphine-induced hyperactivity and suppression of conditioned avoidance responses, however, only Y-931 and clozapine were devoid of cataleptogenic potential. In models of N-methyl-D-aspartate (NMDA) receptor hypofunction, Y-931 demonstrated the most potent protective action against the dizocilpine-induced neurotoxicity (neuronal vacuolization) in the rat retrosplenial cortex ([Y-931 (ED(50); 0.20 mg/kg, p.o.), olanzapine (1.1), clozapine (5.7), risperidone (6.9), haloperidol (19)). Furthermore, Y-931 and clozapine, unlike the other antipsychotics used, reversed the dizocilpine-induced social deficits at the same doses at which their n...Continue Reading
Citations
Jun 13, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·István GyertyánZsolt Szombathelyi
Nov 6, 2010·Psychopharmacology·Mirjana CarliRoberto W Invernizzi
May 26, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johan P RungMaria L Carlsson
Feb 24, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kenji HashimotoMasaomi Iyo
Jan 18, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lin ZhangKenji Hashimoto
Jun 5, 2002·Chemical & Pharmaceutical Bulletin·Toshiyuki KoharaMasafumi Arita
Dec 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Noboru HiroiSoh Agatsuma
Apr 27, 2010·Pharmacology, Biochemistry, and Behavior·C L Danna, G I Elmer
Jan 25, 2013·Synapse·Michael J GlassVirginia M Pickel
Jul 2, 2010·British Journal of Pharmacology·J R Docherty, A R Green
Jul 23, 2013·Neurochemistry International·Fukie Niijima-YaoitaKoichi Tan-No
Apr 23, 2004·Expert Opinion on Investigational Drugs·Ann M Mortimer
Aug 23, 2011·Brain Research Bulletin·Shunsuke MaeharaHisashi Ohta
Apr 5, 2011·Behavioural Brain Research·Anand GururajanDaniel Thomas Malone
Jul 7, 2012·Neuropharmacology·Emilio RussoGiovambattista De Sarro
Dec 4, 2003·Journal of Pharmacological Sciences·Yasuyuki ShiigiDaniel E Casey
Nov 7, 2016·Neuroscience·Rika KasaharaKazuya Sobue
Apr 13, 2012·Journal of Psychopharmacology·Anand GururajanDaniel T Malone
Oct 28, 2003·Synapse·Yoshio MinabeCharles R Ashby
Nov 7, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Naoe OkamuraMasaomi Iyo
Aug 17, 2021·Journal of Clinical Pharmacology·James R Docherty, Hadeel A Alsufyani